Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Pancreatic Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Gastric Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Uterine Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Head and Neck Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Solid Tumors

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Liver Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Cervical Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Testicular Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: SCLC
USOR Number: 16240

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

  • Details

ClinicalTrials.gov ID: NCT04265534
Diagnosis Type: NA
USOR Number: 19239

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

CA20973L: A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

  • Details

ClinicalTrials.gov ID: NCT04026412
Diagnosis Type: NA
USOR Number: 19088

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Esophageal Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

  • Details

ClinicalTrials.gov ID: NCT03748134
Diagnosis Type: NA
USOR Number: 20171

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lymphomas

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

  • Details

ClinicalTrials.gov ID: NCT03646123
Diagnosis Type: Hodgkins
USOR Number: 18013

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Phase III, Randomized, Double-Blind, Placebo-controlled study of Atezolizumab plus Carboplatin and Etoposide with or without Tiragolumab (Anti-Tigit Antibody) in patients with untreated extensive-stage small cell lung cancer (GO41767)

  • Details

ClinicalTrials.gov ID: NCT04256421
Diagnosis Type: NA
USOR Number: 19193

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

20190009: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C

  • Details

ClinicalTrials.gov ID: NCT04303780
Diagnosis Type: NA
USOR Number: 19143

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

  • Details

ClinicalTrials.gov ID: NCT03447769
Diagnosis Type: NA
USOR Number: 17167

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

  • Details

ClinicalTrials.gov ID: NCT03288545
Diagnosis Type: NA
USOR Number: 20172

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Pages